Vulvar melanoma: A report of 20 cases and review of the literature

Journal of the American Academy of Dermatology

Volumn 50, Issue 4, 2004, Pages 554-562

  Wechter, Mary Ellen ^a,b   Gruber, Stephen B ^a,c   Haefner, Hope K ^a,b   Lowe, Lori ^a,b   Schwartz, Jennifer L ^a,b   Reynolds, Kevin R ^a,b   Johnston, Carolyn M ^a,b   Johnson, Timothy M ^a,b,d  

^a Univ Michigan Compreh Cancer Ctr ^*

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOCORTIN 1 RECEPTOR;

ADULT; AGED; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL FEATURE; FAMILY HISTORY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SENTINEL LYMPH NODE BIOPSY; VULVA CANCER;

EID: 1642343375     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.07.026     Document Type: Article

References (65)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.
2. Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, Lagerlof B, Ringborg UK. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999;86:1285-93.
3. Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlof B, Nilsson BR, Ringborg UK. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. Cancer 1999;86:1273-84.
4. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30.
5. Box NF, Wyeth JR, O'Gorman LE, Martin NG, Sturm RA. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997;6:1891-7.
6. Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 1994;171:1225-30.
7. Bradgate MG, Rollason TP, McConkey CC, Powell J. Malignant melanoma of the vulva: a clinicopathological study of 50 women. Br J Obstet Gynaecol 1990;97:124-33.
8. Phillips GL, Bundy BN, Okagaki T, Kucera PR, Stehman FB. Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group. Cancer 1994;73:2626-32.
9. Trimble EL, Lewis JL Jr, Williams LL, Curtin JP, Chapman D, Woodruff JM, et al. Management of vulvar melanoma. Gynecol Oncol 1992;45:254-8.
10. Podratz KC, Gaffey TA, Symmonds RE, Johansen KL, O'Brien PC. Melanoma of the vulva: an update. Gynecol Oncol 1983;16:153-68.
11. Johnson A, Mathai G, Robinson WA. Malignant melanoma of the perineum. J Surg Oncol 1993;54:185-9.
12. Davidson T, Kissin M, Westbury G. Vulvo-vaginal melanoma-should radical surgery be abandoned? Br J Obstet Gynaecol 1987;94:473-6.
13. Rogo KO, Andersson R, Edbom G, Stendahl U. Conservative surgery for vulvovaginal melanoma. Eur J Gynaecol Oncol 1991;12: 113-9.
14. DeMatos P, Tyler D, Seigler HF. Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery 1998;124:38-48.
15. Gonzalez-Bosquet J, Garcia Jimenez A, Gil Moreno A, Xercavins J. Malignant vulvo-vaginal melanoma: a report of 7 cases. Eur J Gynaecol Oncol 1997;18:63-7.
16. Ghurani GB, Penalver MA. An update on vulvar cancer. Am J Obstet Gynecol 2001;185:294-9.
17. Look KY, Roth LM, Sutton GP. Vulvar melanoma reconsidered. Cancer 1993;72:143-6.
18. Tasseron EW, van der Esch EP, Hart AA, Brutel de la Riviere G, Aartsen EJ. A clinicopathological study of 30 melanomas of the vulva. Gynecol Oncol 1992;46:170-5.
19. Johnson TL, Kumar NB, White CD, Morley GW. Prognostic features of vulvar melanoma: a clinicopathologic analysis. Int J Gynecol Pathol 1986;5:110-8.
20. Raspagliesi F, Ditto A, Paladini D, Fontanelli R, Stefanon B, Dipalma S, et al. Prognostic indicators in melanoma of the vulva. Ann Surg Oncol 2000;7:738-42.
21. Piura B, Rabinovich A, Dgani R. Malignant melanoma of the vulva: report of six cases and review of the literature. Eur J Gynaecol Oncol 1999;20:182-6.
22. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993;3:395-401.
23. Isenberg A, Paul Shackelford D. The value of tan lines: vulvar melanoma and ultraviolet rays. Obstet Gynecol Surv 2001;56: 377-80.
24. Gruber SB, Barnhill RL, Stenn KS, Roush GC. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol 1989;21:773-80.
25. Ceballos PI, Ruiz-Maldonado R, Mihm MC Jr. Melanoma in children. N Engl J Med 1995;332:656-62.
26. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-86.
27. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
28. Smith CH, McGregor JM, Barker JN, Morris RW, Rigden SP, MacDonald DM. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993;28:51-5.
29. Dong C, Hemminki K. Second primary neoplasms among 53,159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001; 85:997-1005.
30. Tucker MA, Misfeldt D, Coleman CN, Clark WH Jr, Rosenberg SA. Cutaneous malignant melanoma after Hodgkin's disease. Ann Intern Med 1985;102:37-41.
31. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5: 1663-6.
32. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001;69:774-9.
33. Gantz I, Yamada T, Tashiro T, Konda Y, Shimoto Y, Miwa H, et al. Mapping of the gene encoding the melanocortin-1 (alpha-melanocyte stimulating hormone) receptor (MC1R) to human chromosome 16q24.3 by fluorescence in situ hybridization. Genomics 1994;19:394-5.
34. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-73.
35. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
36. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-83.
37. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19: 3635-48.
38. Johnson TM, Smith JW, Nelson BR, Chang A. Current therapy for cutaneous melanoma. J Am Acad Dermatol 1995;32:689-707.
39. Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579-86.
40. Scheistroen M, Trope C, Kaern J, Abeler VM, Pettersen EO, Kristensen GB. Malignant melanoma of the vulva FIGO stage I: evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment. Gynecol Oncol 1996;61:253-8.
41. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al, editors. SEER cancer statistics review, 1973-1999, National Cancer Institute. 2002. Available at: http://seer.cancer.gov/csr/1973_1999/. Accessed May 18, 2003.
42. Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM. Thin primary cutaneous melanomas. Cancer 2002;95:1562-8.
43. Trimble EL. Melanomas of the vulva and vagina. Oncology (Huntingt) 1996;10:1017-23.
44. Look KY. Organ sparing management for carcinoma of the vulva and vagina. Eur J Gynaecol Oncol 2000;21:439-46.
45. Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 1998;178: 1177-84.
46. Irvin WP Jr, Bliss SA, Rice LW, Taylor PT Jr, Andersen WA. Malignant melanoma of the vagina and locoregional control: radical surgery revisited. Gynecol Oncol 1998;71:476-80.
47. Rose PG, Piver MS, Tsukada Y, Lau T. Conservative therapy for melanoma of the vulva. Am J Obstet Gynecol 1988;159:52-5.
48. Lotem M, Anteby S, Peretz T, Ingber A, Avinoach I, Prus D. Mucosal melanoma of the female genital tract is a multifocal disorder. Gynecol Oncol 2003;88:45-50.
49. Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure. J Am Acad Dermatol 1997;37: 758-64.
50. Anderson KW, Baker SR, Lowe L, Su L, Johnson TM. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001;3:202-6.
51. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997;225:1-14.
52. De Cicco C, Sideri M, Bartolomei M, Grana C, Cremonesi M, Fiorenza M, et al. Sentinel node biopsy in early vulvar cancer. Br J Cancer 2000;82:295-9.
53. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 19:2851-5.
54. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
55. Su LD, Lowe L, Bradford CR, Yahanda AI, Johnson TM, Sondak VK. Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol 2002;46:661-6.
56. Uren RF, Howman-Giles R, Thompson JF, McCarthy WH, Quinn MJ, Roberts JM, et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg 2000;135:1168-72.
57. Levenback C, Burke TW, Gershenson DM, Morris M, Malpica A, Ross MI. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol 1994;84:163-7.
58. Ramirez PT, Levenback C. Sentinel nodes in gynecologic malignancies. Curr Opin Oncol 2001;13:403-7.
59. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 2001;83:276-81.
60. Abramova L, Parekh J, Irvin WP Jr, Rice LW, Taylor PT Jr, Anderson WA, et al. Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review. Ann Surg Oncol 2002;9:840-6.
61. Terada KY, Shimizu DM, Wong JH. Sentinel node dissection and ultrastaging in squamous cell cancer of the vulva. Gynecol Oncol 2000;76:40-4.
62. Paganelli G, De Cicco C, Chinol M. Sentinel node localization by lymphoscintigraphy: a reliable technique with widespread applications. Recent Results Cancer Res 2000;157:121-9.
63. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, DeConti R, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-24.
64. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469-74.
65. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-63.